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ABSTRACT 
The present research is an approach to develop a formulation platform that shall help in minimizing the time and effort taken to develop a drug 
delivery system. Taking bilayer tablet technology as a representation for drug delivery system, well accepted antihypertensive drugs, Amlodipine 
besylate and Metoprolol succinate were considered as model drugs for the study. Initially the process variables like concentration of the 
disintegrants, Sodium starch Glycolate and cross carmellose sodium, Polymers HPMC K100M and K4M were standardized with these drugs so that 
the incorporation of a new combination drugs would provide predictable results with a minimal trial runs. Nebivolol hydrochlo ride and Valsartan 
were considered as test drugs since they are novel antihypertensive drug combination and their physicochemical and pharmacokinetic parameters 
were almost similar to that of the model drugs. The r value 0.98943 indicates a good correlation between the release profile of Amlodipine besylate 
(model drug) and Nebivolol hydrochloride (test drug) from the IR layer. Similarly, the r value in the range of 0.9998 indicates a good correlation 
between the release profile of Metoprolol succinate (model drug) and Valsartan (test drug) from the SR layer. The comparable experimental results 
of the model drugs and test drugs considered for this study infer that if two drugs are similar in their physicochemical and pharmacokinetic 
parameters, their behavior with respect to in vitro parameters will be similar provided formulation variables remains constant. This concept could 
be productive in developing drug delivery system for new drugs for which extensive research and time are major constraints.  
Keywords: Bilayer tablets, fixed unit dosage form, Amlodipine besylate, Metoprolol Succinate Nebivolol hydrochloride, Valsartan. 
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INTRODUCTION 
Developing a useful drug delivery system is a result of 
concerned efforts by the scientist of variety of disciplines who 
recognize the need and potential for improving 
pharmcotherapeutics through the development of novel drug 
delivery systems. The method by which a drug is delivered can 
have a significant effect on its efficacy. Some drugs have an 
optimum concentration range within which maximum benefit 
is derived, and concentrations above or below this range can 
be toxic or produce no therapeutic benefit at all. In recent 
times, many guidelines emphasize that the majority of the 
hypertensive population will require two or more 
antihypertensive drugs to achieve the recommended 
treatment goals.1  
Fixed drug combinations (FDCs) of antihypertensive agents 
have proven to be efficacious in the treatment of hypertension. 
The availability of many antihypertensive agents in various 
classes such as diuretics, calcium channel blockers (CCBs), 
angiotensin converting enzyme inhibitors, angiotensin 
receptor blockers, β adrenoceptor blockers are frequently 
combined in FDCs. 
A combination of a calcium channel blocker (CCB) Amlodipine 
besylate with a β adrenoceptor blocker Metoprolol succinate is 
advantageous since, their modes of action are different yet 
their action on blood pressure (BP) is complementary. The β 
adrenoceptor blocker might regulate any CCB-induced acute 
reflex increase in sympathetic activity and conversely, the CCB 
might compensate the peripheral vasospasm and drop in 
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cardiac output caused by the β adrenoceptor blocker; thus, 
reducing the overall burden of side-effects. This is one key to 
ensure better long-term compliance with therapy and to more 
effective long-term BP control.2  
Metoprolol succinate and Amlodipine Besylate are in the 
market for the past two decades or so. These drugs have been 
extensively researched in various dimensions for optimal 
hypertension therapy. Hence they were considered as model 
drugs to develop bilayer tablets which shall help in developing 
bilayer tablets of recently approved fixed dose combination of 
Nebivolol Hydrochloride and Valsartan for hypertension. 
MATERIALS AND METHODS 
Metoprolol succinate, Amlodipine Besylate, Nebivolol 
hydrochloride and Valsartan were received as gift samples 
from Apotex Pharmachem India Pvt. Ltd, Bengaluru, India. The 
polymers such as Hydroxypropyl Methylcellulose K100M 
(Methocel K100M premium), K4M (Methocel K4M premium), 
Dibasic calcium phosphate (anhydrous, FCC), sodium starch 
glycolate (731713H), croscarmellose sodium(Ac di sol NF), 
FD&C blue lake, microcrystalline cellulose, silicon dioxide 
(Aerosil 200) and magnesium stearate (ligamed MF) were 
obtained from KMS Pharma - Formulation development 
Healthcare Pvt Ltd, Chennai, India.  
The present research was carried out in two phases. The phase 
I consisted of formulation and evaluation of bilayer tablets of 
model drugs Amlodipine besylate and Metoprolol succinate for 
immediate release (IR) and sustained (SR) respectively. The II 
phase consisted of formulation and evaluation of bilayer 
tablets of test drugs Nebivolol hydrochloride and Valsartan in 
IR and SR respectively. 
Phase I:  Bilayer tablets of Amlodipine besylate and 
Metoprolol succinate 
Selection of excipients 
The excipients necessary for formulation was selected based 
on the relevant information from the literature survey on 
previous research on the same ideology. The excipients which 
influence modified release in the bilayer tablets such as 
superdisintegrants: Sodium Starch Glycolate, Croscarmellose 
sodium and the percentage of polymers like Hydroxypropyl 
Methylcellulose K100M, K4M were optimized by reference 
articles.3 The selected excipients were subjected for 
incompatibility studies with the drugs. 
The ingredients after sifting, prelubrication and blending was 
subjected for precompression parameters like excipient 
compatibility studies, Angle of Repose, Bulk Density, Tapped 
Density Carr’s. Index (%), Hausner’s Ratio.4 (Table 1) the 
Fourier-transform infrared spectroscopy (FTIR) studies were 
done for standard Amlodipine Besylate, Metoprolol succinate 
and Excipients. 
 
Table 1: Pre-compression Parameters of immediate and sustained release layers 
Formulation 
Angle of 
Repose* 
Bulk Density* 
(g/ml) 
Tapped 
Density* (g/ml) 
Carr’s Index * 
(%) 
Hausner’s 
Ratio* 
F1 27.1°±0.03 0.365±0.0006 0.581± 0.0021 37.17± 0.74 1.591± 0.009 
F2 28°±0.32’ 0.362±0.0007 0.579± 0.0023 37.47± 0.76 1.599± 0.007 
F3 29°±0 32’ 0.360±0.0005 0.584± 0.0018 38.35± 0.75 1.622± 0.005 
F4 28°±035’ 0.362±0.0007 0.580± 0.0019 37.58± 0.78 1.580± 0.006 
F5 28°±045’ 0.364±0.0081 0.582± 0.0022 37.45± 0.79 1.598± 0.009 
F6 28°±053’ 0.370±0.0082 0.578±0.0024 37.98± 0.74 1.562± 0.004 
F7 280±010’ 0.340+0.0073 0.548+ 0.0037 37.65+ 0.79 1.611+ 0.006 
F8 290±033’ 0.351+0.0008 0.568+ 0.0036 38.20+ 0.78 1.618+ 0.008 
F9 280±065’ 0.372+0.0091 0.592+ 0.0041 37.16+ 0.76 1.591+ 0.089 
F10 290±044’ 0.365+0.0092 0.587+ 0.0042 37.81+ 0.75 1.608+ 0.091 
Where, *All values are mean ± SD, n=3, 
 
Formulation of Bi-layer tablets: 
Bi-layer tablets of extended release Metoprolol succinate and 
immediate release Amlodipine Besylate were prepared 
through direct compression method according to the 
composition shown in Table 2. Various step like sifting, dry 
mixing, prelubrication and lubrication was carried out prior 
direct compression process. 
Preparation of Amlodipine Besylate immediate release (IR) 
layer: 
Amlodipine Besylate immediate release tablets were prepared 
by using direct compression method. The microcrystalline 
cellulose, Dicalcium phosphate, Pregelatinised starch, sodium 
starch gluconate and the active ingredient were passed 
through sieve no. 30 and mixed homogenously. Magnesium 
stearate and Aerosil were passed through sieve no.60 and 
added as a lubricant to the above dry mix and mixed well for 5 
minutes. Finally the colorant FD &C blue lake was sieved 
through sieve no.100 mesh and then mixed with the dry mix 
homogenously to get uniform blend without mottling.  
Preparation of Metoprolol sustained release (SR) layer: 
The active ingredient Metoprolol succinate, was passed 
through the 40 mesh sieve followed by the other ingredients. 
Metoprolol succinate, Polymer [Hydroxypropyl 
Methylcellulose K100M (Methocel K100M premium), K4M 
(Methocel K4M premium)] diluents [Dibasic calcium 
Phosphate (anhydrous, FCC)] were taken in a planetary mixer 
and mixed for 15 minutes to ensure uniform mixing of the 
ingredients with the drug.Colloidal slicondioxide (Aerosil-
200), sifted through 40 mesh sieve were mixed with dry mixed 
blend for 5 minutes. 5 
1. Tablet compression: 
 The Bi-layer tablet compression was made using 14/6mm 
punches in Rimek minicompressor II DL. In this, sustained 
release Metoprolol Succinate powder were introduced first in 
to the die cavity and a slight precompression was made so that 
the layer was uniformly distributed. After that immediate 
release Amlodipine Besylate granules were added through the 
other feed and a final compression was made with view to 
maintain the fixed hardness and uniform weight.
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Table 2: Composition of different formulations 
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First layer                 
1 
Amlodipine 
Besylate 
6.8 6.8 6.8 6.8 6.8 6.8 6.8 6.8 6.8 6.8 6.8 6.8 6.8 6.8 6.8 6.8 6.8 6.8 6.8 6.8 
2 
Microcrystalli
ne cellulose 
(Avicel PH 
102) 
37.
95 
37.
95 
32.
95 
32.
95 
34.
95 
34.
95 
34.
95 
34.
95 
32.
95 
32.
95 
37.
95 
37.
95 
37.
95 
37.
95 
37.
95 
37.
95 
37.
95 
37.
95 
37.
95 
37.
95 
3 
Dibasic 
calcium 
Phosphate 
50 50 55 55 55 55 55 55 55 55 50 50 52 52 52 52 50 50 50 50 
4 
Sodium starch 
Glycolate 
4 4 4 4 2 2 0 0 0 0 0 0 2 2 2 2 0 0 0 0 
5 
Croscarmellos
e sodium 
0 0 0 0 0 0 2 2 4 4 4 4 0 0 0 0 4 4 4 4 
6 
FD&C blue 
lake 
0.2
5 
0.2
5 
0.2
5 
0.2
5 
0.2
5 
0.2
5 
0.2
5 
0.2
5 
0.2
5 
0.2
5 
0.2
5 
0.2
5 
0.2
5 
0.2
5 
0.2
5 
0.2
5 
0.2
5 
0.2
5 
0.2
5 
0.2
5 
7 Mg. Stearate 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 
Total 
10
0 
10
0 
10
0 
10
0 
10
0 
10
0 
10
0 
10
0 
10
0 
10
0 
10
0 
10
0 
10
0 
10
0 
10
0 
10
0 
10
0 
10
0 
10
0 
10
0 
Second layer                 
8 
Metoprolol 
Succinate 
57.
5 
28.
75 
57.
5 
28.
75 
57.
5 
28.
75 
57.
5 
28.
75 
57.
5 
28.
75 
57.
5 
28.
75 
57.
5 
28.
75 
57.
5 
28.
75 
57.
5 
28.
75 
57.
75 
28.
75 
9 
Microcrystalline 
cellulose (Avicel 
PH 102) 
88.
5 
44.
25 
10
0.5 
50.
25 
94.
5 
47.
25 
94.
5 
47.
25 
78.
5 
39.
25 
58.
5 
29.
25 
38.
5 
19.
25 
28.
5 
14.
25 
58.
5 
29.
25 
18.
5 
9.2
5 
 
Table 3: Physical characterizations of Bi-layer tablets 
Batch code 
Avg weight 
mg 
Hardness* 
kg 
Thickness* 
mm 
Drug content (%) 
Friability (%) 
 Amlodipine Metoprolol 
F1 285 10.3± 0.1 3.52± 0.024 94.1 91.6 0.54 
F2 299 10.8±0.07 3.63± 0.07 91.7 100.7 0.57 
F3 302 12.4± 0.084 3.64± 0.033 93.1 97.5 0.49 
F4 296 11.4± 0.1 3.62±0.055 92.1 91.5 0.56 
F5 294 12.2±0.063 3.59+ 0.07 93.3 96.6 0.52 
F6 305 11.7±0.1 3.77±0.1 90.9 99.2 0.49 
F7 302 12.4±0.16 3.64± 0.16 93.1 97.5 0.49 
F8 299 10.8+ 0.14 3.63± 0.08 91.7 100.7 0.57 
F9 305 11.7+ 0.09 3.77+ 0.07 90.9 99.2 0.49 
F10 294 12.2+ 0.14 3.59+ 0.12 93.3 96.6 0.52 
Where, *All values are mean ± SD, n=3, 
 
2. In vitro dissolution study 6 
Drug Release Studies for Immediate release (IR) layer  
The in vitro dissolution of immediate release layer was 
determined using USP XXIII (basket method) dissolution 
apparatus. The basket was allowed to rotate at a speed of 100 
rpm and temperature of 37 ± 0.5°C was maintained. The 
dissolution medium used was 900 ml of 0.1N HCl (pH 1.2) for 2 
hours. Aliquots (5 ml) of sample were collected at 30 min from 
the dissolution apparatus and it was replaced with equal 
volume of fresh dissolution medium. The aliquots withdrawn 
were filtered through 0.45µm millipore filters. The 
concentration of Amlodipine in the dissolution media was 
estimated by HPLC method at 239 nm.  
Drug Release Studies for Metoprolol Succinate sustained 
release (SR) layer7 
The in vitro dissolution of sustained release layer was 
determined using USP XXIII (basket method) dissolution 
apparatus. The basket was allowed to rotate at a speed of 100 
rpm and temperature of 37 ± 0.5°C was maintained. The 
dissolution medium used was 900 ml of 0.1N HCl (pH 1.2) for 
the initial 2hours followed by study in simulated intestinal 
fluid Phosphate buffer solution (pH 6.8). Aliquots (5 ml) of 
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sample were collected at predetermined time intervals (1, 4, 8, 
20 hrs) from the dissolution apparatus and it was replaced 
with equal volume of fresh dissolution medium. The aliquots 
withdrawn were filtered through 0.45µm millipore filters. The 
concentration of Metoprolol in the dissolution media was 
estimated by HPLC method at 280 nm.  
Drug Release Studies for Bi-layer Tablets 
The in vitro dissolution of Amlodipine and Metoprolol Bi-layer 
tablets were determined using USP XXIII (basket method) 
dissolution apparatus. The basket was allowed to rotate at a 
speed of 100 rpm and temperature of 37 ± 0.5°C was 
maintained. The dissolution medium used was 900 ml of 0.1N 
HCl (pH 1.2) for the initial 2hours followed by study in 
simulated intestinal fluid Phosphate buffer solution (pH 6.8). 
Aliquots (5 ml) of sample were collected at predetermined 
time intervals (1, 4, 8, 20 hrs) from the dissolution apparatus 
and it was replaced with equal volume of fresh dissolution 
medium. The aliquots withdrawn were filtered through 
0.45µm millipore filters. The concentration of both the drugs in 
the dissolution media was estimated by HPLC method at 239 
nm and 280nm for Amlodipine and Metoprolol respectively.
  
Table 4: Dissolution parameters of Amlodipine IR and Metoprolol ER tablets 
 Particulars Amlodipine Metoprolol 
Dissolution media 0.01N HCl pH 6.80 Phosphate Buffer 
Volume 500ml 500ml 
Model 
USP TYPE II Paddle 
(covered with Parafilm) 
USP TYPE II Paddle 
(covered with Parafilm) 
RPM 75 50 
Time of sampling 30mins 1,4,8,20 Hrs 
 
Table 5: Dissolution profile for Amlodipine Besylate layer 
Time 
(min) 
 
30 
F1* F2* F3* F4* F5* F6* F7* F8* 
 
F9 
 
F10 
% drug released 
100 108.2 103.2 107.4 105.5 102.2 65.4 74.9 95.9 96 
 
±5.08 ±4.6 ±3.53 ±1.48 ±1.5 ±1.94 ±1.54 ±0.62 ±0.5 ± 0.6 
 
 
Figure 1: Drug Release from Amlodipine Besylate IR Layer (spl –trial 1, 2 respectively) 
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Table6: Drug Release from Metoprolol Succinate sustained release (SR) layer 
Time 
in 
hours 
limit of 
%drug 
release 
F1 F2 F3 F4 F5 F6 F7 F8 F9 F10 
MKT 
PD* 
1 
Not more than 
25% 
17.0    
+3.70 
13.0 
+4.95 
12.6  
+4.83 
17.1  
+4.10 
21.4  
+5.53 
22.0  
+5.10 
30.0  
+4.95 
27.6  
+4.83 
19.4  
+5.26 
14.3  
+4.66 
19.1+5.
30 
4 
Between 20% 
and 40% 
31.0  
+2.53 
24.4  
+4.56 
25.2  
+3.79 
29.5  
+2.96 
31.8  
+2.40 
36.6  
+4.38 
56.4  
+4.56 
50.2  
+3.79 
40.2  
+5.80 
33.8  
+4.35 
32.5+4.
43 
8 
Between 40% 
and 60% 
51.2  
+2.25 
47.1  
+2.84 
49.6  
+3.73 
47.2  
+3.43 
49.7  
+2.81 
59.5  
+3.33 
75.1  
+2.84 
70.6  
+3.73 
62.1  
+1.78 
51.9  
+3.52 
54.6 
+4.75 
20 
Not less than 
80% 
98.4   
+1.83 
99.7  
+1.67 
99.5  
+1.42 
100  
+1.63 
96.1  
+0.70 
98.4  
+0.88 
97.7  
+1.67 
97.5  
+1.42 
97.9  
+0.98 
96.5  
+3.28 
99.6 
+1.02 
*MKT PD*: Marketed product 
 
 
Figure 2: Drug Release from Metoprolol Succinate SR layer for 
formulations 1 to 5 
 
 
Figure 2A: Drug Release from Metoprolol SR Layer for 
formulations 6 to 10
Table 7: Release kinetics 
Correlation 
coefficient 
Model 
Formulation 
code 
Zero order Higuchi Korsemeyer peppas 
F1 0.99962 0.98728 0.81490 
F2 0.99555 0.97312 0.85230 
F3 0.99415 0.97665 0.85596 
F4 0.99181 0.97914 0.81456 
F5 0.98212 0.98677 0.78028 
F10 0.98395 0.99187 0.83323 
 
Interpretation of the kinetic studies: 
 The r value for zero order release indicates the SR layer 
containing valsartan follows zero order release pattern 
where in the drug release at any moment is independent 
of the initial concentration.  
 The r value for Higuchi model infers the SR layer follows 
a drug release by diffusion process based on Fickian law 
of diffusion.  
 The r value for Peppas model shows moderate linearity.  
 
Phase II: Bilayer tablets of Nebivolol Hydrochloride and 
Valsartan 
In the best formulation selected from Phase I experiments, 
Amlodipine besylate was replaced with Nebivolol 
hydrochloride and Metoprolol succinate was replaced with 
Valsartan. These drugs were considered as main drugs since 
the combination is novel and has many therapeutic benefits.9 
Rationale for drug selection 
Recently, fixed dose combination of Nebivolol hydrochloride, a 
selective β1 antagonist and valsartan an angiotensin II 
receptor blocker was approved by USFDA for hypertension. 
Pharmacological profiles of Nebivolol hydrochloride and 
valsartan alone and in combination are well characterized. In 
addition, a large 8-week randomized trial in stages I–II 
hypertensive patients (N=4161) demonstrated greater blood 
pressure-reducing efficacy for 33Neb/valsartan SPCs than 
component monotherapies with comparable tolerability. In a 
biomarkers sub study (N=805), Nebivolol/valsartan single-pill 
combination prevented valsartan-induced increases in plasma 
renin, and a greater reduction in plasma aldosterone was 
observed with the highest single-pill combination dose vs. 
valsartan 320 mg/day.10 
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Nebivolol, a new anti-hypertensive drug with peripheral 
vasodilating properties and adrenoceptor antagonism, given in 
monotherapy, is as effective as amlodipine in reducing clinical 
BP in elderly patients with essential hypertension, but it is 
better tolerated and has the additional advantage of reducing 
sympathetic discharge. Nebivolol may therefore be 
recommended as a first-line treatment option for the 
management of elderly patients with mild to moderate 
uncomplicated essential hypertension.11 
Valsartan is an angiotensin II receptor antagonist that is used 
in the treatment of hypertension. It act by blocking the binding 
of angiotensin II and I to its receptors thereby blocking 
vasoconstrictor and aldosterone secreting effect of angiotensin 
II selectively. The most preferred route for this drug is oral 
delivery in the form of tablets. Valsartan has poor water 
solubility, low bioavailability (approximately 20-25%) and 
short half-life (nearly hrs.) which makes it an ideal candidate 
for sustained release. Hence in the present work this ideology 
is adopted.12 
A comparative physicochemical properties of the four drugs in 
study has been summarized in table 8. The values show that 
the model drugs and the test drugs are comparable in their 
physicochemical and pharmacokinetic properties thus 
justifying the selection and replacement of the model drugs in 
the phase I study with the test drugs. Further, similarities in 
the behavior of the test drugs to the model drugs with respect 
to the precompression and post compression parameters can 
be understood by formulating the test drugs and evaluating 
them in same manner as that of the model drugs.
 
Table 8: Comparative physicochemical parameter of the drugs13, 14, 15, 16, 17, 18, 19 
Parameter 
Drugs for immediate release Drugs for sustained  release 
Amlodipine 
besylate (model 
drug) 
Nebivolol 
hydrochloride(test 
drug) 
Metoprolol 
succinate (model 
drug) 
Valsartan(test drug) 
Solubility in pH 
1.2/ 6.8* 
Highly soluble Highly soluble Good solubility Low solubility 
Solubility in pH 6.8* Less soluble Less soluble Highly soluble Highly soluble 
Lipid solubility Highly soluble Highly soluble Highly soluble Highly soluble 
Existence Weak acid Weak acid Weak base acidic 
pKa 8.60 8.13 9.6 8.15 
Permeability Highly permeable Highly permeable Highly permeable 
Low permeable in pH. 1.2, 
highly permeable in pH 6.8 
Bioavailability 64-90% 12-96% 50%  
Protein binding 93% 98% 12% 94 to 97% 
t half 30-40 hrs 10 to 31hrs 3-7h 4-6 hr. 
Tmax 3-8hrs 0.5-4hrs 1.5 – 2.0 h 1.0 – 2.0 hr. 
Volume of 
distribution 
21 L/kg 17.3-184L/kg 3.2 - 5.6 L/kg. 17 L 
clearance 21h 16-657L/h 1 L/minute. 0.62 L/hr 
Partition coefficient 2.66 4.03 1.57 0.033 
 
Formulation of Bi-layer tablets: 
The ingredients after sifting, Prelubrication and blending was 
subjected for precompression parameters like excipient 
compatibility studies, Angle of Repose, Bulk Density, Tapped 
Density Carr’s. Index (%), Hausner’s Ratio.20 The results are 
shown in table 9 and 10. The studies were done for standard 
Nebivolol HCl, Valsartan and Excipients.
 
Table 9: Pre-compression Parameters of Nebivolol hydrochloride 
Formulation Angle of 
Repose* 
Bulk Density* Tapped 
Density* 
Carr’s. Index 
(%)* 
Hausner’s 
Ratio* 
B1 28°.46’±0.26 0.6130±0.0071 0.799±0.0021 23.28±0.71 1.304±0.008 
B2 28°.46’±0.35 0.613±0.0071 0.799±0.0024 23.28±0.75 1.304±0.007 
B3 28°.46’±0.72 0.613±0.091 0.799v0.0019 23.28±0.80 1.304±0.098 
B4 27°.23’±0.27 0.597±0.0091 0.789±0.0030 23.94±0.69 1.315±0.009 
B5 27°.23’±0.34 0.597±0.0092 0.789±0.0023 23.94±0.73 1.315±0.089 
B6 27°.23±0.70 0.597±0.0074 0.789±0.0018 23.94±0.79 1.315±0.097 
Where, *All values are mean ± SD, n=3, 
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Table10: Pre-compression Parameters of Valsartan 
Formulation Angle of 
Repose* 
Bulk Density* Tapped 
Density* 
C. Index (%)* Hausner’s 
Ratio* 
B1 270.28’±0.27 0.329±0.0094 0.5280±0.0019 37.73±0.77 1.606±0.007 
B2 280.10’±0.71 0.335±0.0075 0.533±0.0025 37.25±0.74 1.594±0.006 
B3 280.35’±0.77 0.305±0.008 0.536±0.0028 38.137±0.81 1.759±0.097 
B4 280.32’±0.49 0.350±0.009 0.534±0.0026 34.42±0.79 1.525±0.078 
B5 280.36’±0.25 0.333±0.0069 0.522±0.0024 36.26±0.82 1.569±0.008 
B6 280.56’±0.78 0.306±0.0077 0.486±0.0029 36.98±0.74 1.587±0.087 
Where, *All values are mean ± SD, n=3, 
 
Six formulations of bilayer tablets were prepared with the 
variation of excipients as mentioned Table 11. Various steps 
(Sifting, Dry mixing, Prelubrication and Lubrication) involved 
in direct compression process. The formulation procedure 
was same as the formulation of model drugs. The compressed 
tablets were analyzed for post compression parameters. The 
details of the results are shown in Table 12. 
  
Table 11: Composition of Nebivolol Hydrochloride and Valsartan in IR layer and SR layer 
 
Table 12:  Physical characterizations of Bi-layer tablets. 
BATCH 
CODE 
AVG. WT. (mg) 
HARDNESS(kg
/cm2 ) 
Thickness (mm) 
DRUG CONTENT (%) FRIABILITY 
(%) Nebivolol Valsartan 
B1 304.3±1.24 17.3±4.31 3.91±2.31 91.27 95.65 0.58±2.36 
B2 296.0±2.72 15.93±5.21 3.89±2.35 90.75 95.49 0.56±4.21 
B3 306.2±4.24 17.34±6.32 3.91±3.52 91.27 95.65 0.54±1.23 
B4 303.2±3.21 18.67±3.5 3.92±4.12 91.27 95.65 0.58±4.21 
B5 302.9±1.52 17.77±2.31 3.91±4.36 90.75 95.65 0.55±2.36 
B6 304.2±3.23 12.64±4.21 4.13±2.42 91.27 95.49 0.56±4.25 
All values are mean ± SD, n=3, 
 
 
Nebivolol Hydrochloride and Valsartan Bilayer tablets 
Formulation Plan 
 
S.N
o 
Ingredients 
B1 B2 B3 B4 B5 B6 
mg/T
ab 
%W/
W 
mg/T
ab 
%W/
W 
mg/T
ab 
%W/
W 
mg/T
ab 
%W/
W 
mg/T
ab 
%W/
W 
mg/T
ab 
%W/
W 
First layer 
1 
Nebivolol 
Hydrochloride 
5 5 5 5 5 5 5 5 5 5 5 5 
2 
Microcrystalline 
cellulose (Avicel 
PH 102) 
37.95 37.95 32.95 32.95 34.95 34.95 34.95 34.95 32.95 32.95 37.95 37.95 
3 
Dibasic calcium 
Phosphate 
51.8 51.8 51.8 51.8 51.8 51.8 51.8 51.8 51.8 51.8 51.8 51.8 
4 
Sodium starch 
Glycolate 
4 4 4 4 4 4 0 0 0 0 0 0 
5 
Croscarmellose 
sodium 
0 0 0 0 0 0 4 4 4 4 4 4 
6 FD&C blue lake 0.25 0.25 0.25 0.25 0.25 0.25 0.25 0.25 0.25 0.25 0.25 0.25 
7 Mg. Stearate 1 1 1 1 1 1 1 1 1 1 1 1 
Total 100 100 100 100 100 100 100 100 100 100 100 100 
Second layer 
8 valsartan 60 23.75 60 23.75 60 23.75 60 23.75 60 23.75 60 23.75 
9 
Microcrystalline 
cellulose (Avicel 
PH 102) 
86 49.25 98 55.25 91 52.25 92 52.25 76 44.25 16 34.25 
10 HPMC K100M 50 25 38 19 44 22 0 0 0 0 0 0 
11 HPMC K4M 0 0 0 0 0 0 44 22 60 30 120 40 
12 Sio2 2 1 2 1 2 1 2 1 2 1 2 1 
13 Mg. Stearate 2 1 2 1 2 1 2 1 2 1 2 1 
Total 200 100 200 100 200 100 200 100 200 100 200 100 
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In vitro dissolution study  
All parameters, conditions and procedure for the study was similar to the phase I dissolution studies. 
Table 13: Drug Release from Valsartan sustained release (SR) layer 
 
B1 
B2 
 
B3 
B4 
 
B5 
 
B6 
 
Time 
Hrs 
%CDR %CDR %CDR %CDR %CDR %CDR 
0 0 0 0 0 0 0 
1 11±8.94 12±7.45 18±22.41 11±0.00 9±9.94 10±0.00 
4 25±11.50 25±6.20 30±1.36 27±2.03 24±16.81 24±6.46 
8 37±7.77 39±8.70 46±3.00 43±4.01 38±14.49 40±2.58 
20 64±5.17 66±5.91 80±5.92 79±8.50 70±13.66 72±0.57 
24 71±3.64 76±5.92 84±6.76 87±9.33 80±13.80 81±2.92 
All values are mean ± SD, n=6. , % CDR is percent cumulative drug release 
 
Figure 3: Drug Release from Valsartan SR layer for formulations B1 to B6, %CDR is percent cumulative drug release 
Table 14: Drug Release from Nebivolol hydrochloride immediate release (SR) layer 
I set Dissolution of IR1 with SR1,SR,SR3 Time mins 
15 30 
B1 65±3.94 79±7.36 
B2 71±4.91 83±1.77 
B3* 79±6.72 92±3.47 
II set DIssolution of IR2with SR4,SR5,SR6  
B4 71±5.49 83±6.17 
B5 67±1.12 835.25 
B6 74±22.31 81±4.73 
All values are mean ± RSD, n=6. 
Figure 4: Drug Release from Nebivolol Hydrochloride IR 
layer for formulations B1, B2 and B3 
 
Figure 4A: Drug Release from Nebivolol Hydrochloride IR 
layer for formulations B4 to B6 
The results of immediate release and sustained release layers were compared to analyze the similarities in the behavior. 
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Table 15: comparative release profile of Amlodipine besylate and Nebivolol hydrochloride from immediate release (IR) 
layers 
Time in min Formulation code 
Amlodipine 
besylate(%CDR) 
Nebivolol 
hydrochloride(%CDR) 
30 F1 vs B1 100±5.08 79±7.36 
30 F2 vs B2 108.2±4.6 83±1.77 
30 F3 vs B3 103.2±3.53 92±3.47 
30 F4 vs B4 107.4±1.48 83±6.17 
30 F5 vs B5 105.5±1.5 83±5.25 
30 F10 vs B6 96± 0.6 81±4.73 
Correlation coefficient r=0.9894378 
 
 
Figure 5: comparative release profile of Amlodipine besylate and Nebivolol hydrochloride from immediate release (IR) layers 
Table 16: Comparative release profile of Metoprolol succinate and Valsartan from sustained release layer (SR) 
Time hrs. F1 B1 F2 B2 F3 B3 F4 B4 F5 B5 F10 B6 
0 0 0 0 0 0 0 0 0 0 0 0 0 
1 17.0    
+3.70 
11±8.9
4 
13.0 
+4.95 
12±7.4
5 
12.6  
+4.83 
18±22.
41 
17.1  
+4.10 
11±0.0
0 
21.4  
+5.53 
9±9.94 14.3  
+4.66 
10±0.0
0 
4 31.0  
+2.53 
25±11.
50 
24.4  
+4.56 
25±6.2
0 
25.2  
+3.79 
30±1.3
6 
29.5  
+2.96 
27±2.0
3 
31.8  
+2.40 
24±16.
81 
33.8  
+4.35 
24±6.4
6 
8 51.2  
+2.25 
37±7.7
7 
47.1  
+2.84 
39±8.7
0 
49.6  
+3.73 
46±3.0
0 
47.2  
+3.43 
43±4.0
1 
49.7  
+2.81 
38±14.
49 
51.9  
+3.52 
40±2.5
8 
20 98.4   
+1.83 
64±5.1
7 
99.7  
+1.67 
66±5.9
1 
99.5  
+1.42 
80±5.9
2 
100  
+1.63 
79±8.5
0 
96.1  
+0.70 
70±13.
66 
96.5  
+3.28 
72±0.5
7 
Correlation 
coefficient 
 0.999925 
 
0.986814 
 
0.990130 0.99445 
 
0.99322 
 
0.999498 
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Figure 6: Comparative sustained release profile of model and test drugs (F series contain Metoprolol succinate and B series contain 
Valsartan) 
RESULTS AND DISCUSSION 
Different formulations of Bi-layer tablets were prepared and 
evaluated with an idea to develop Metoprolol Succinate and 
Amlodipine Besylate as model drugs to be incorporated in 
sustained release layer and as an immediate release layer 
respectively. This idea will help in improving hypertension 
therapy of two drugs and patient’s compliance. These two 
drugs are extensively researched in various formulations for 
the past two decades. Hence they were considered as model 
drugs for the present study. 
Direct compression method was selected for the formulation. 
The polymers and other excipients were selected based on the 
literature survey and satisfying results produced during drug-
excipients compatibility studies to develop the final 
formulation (Table.1). In Phase I experiments, bulk density in 
the range of 0.3 -0.6 gm/cm3indicates a good packing 
characteristics. The Carr’s compressibility index was found to 
be in the range of 37-38 % which suggested optimal 
compressibility. The values of Hausner ratio where found in 
the range of 1.5 to 1.6 suggested optimal flowability of powder 
blend. The angle of repose of all the blend was within range of 
27 to 28 indicated excellent flow property of powder blend. 
The bilayer tablets were evaluated for different physical 
parameter (Table 1). The hardness of bilayer tablet was found 
in the range of 10 to 12 kg/cm2 which was more as compared 
to individual layer because of double compression. The 
thickness of the bilayer tablet was in the range of 3.5 – 3.7 mm 
which is an excellent value for double layer. The friability was 
0.49- 0.54% for bilayer tablet which was less than 1 indicating 
good handling of tablet. The weight variation study showed 
low standard deviation uniformity in weight of the tablets 300 
± 0.06mg. (Table 3)  
In the composition of Amlodipine Besylate immediate release 
layer, superdisintegrants sodium starch glycolate and 
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Croscarmellose sodium were used in the range of 2 to 4 mg per 
tablet. The results of drug release from IR layer, infers that at 
the concentration of 2 to 4 mg both the super disintegrants 
comply with the limit for drug release in 30 min(Table:5, fig 1) 
In the formula for Metoprolol Succinate sustained release 
layer, Hydroxy Propyl Methyl Cellulose (HPMC K 100 M) and 
HPMC K4M were used as retardant polymers. From the drug 
release profile it infers that Hydroxy Propyl Methyl Cellulose 
(HPMC K 100 M) at a concentration of 50 to 60% produced 
desired release profile for Metoprolol Succinate extended 
release layer as per USP limits. F1, F2, F3, F4, F5and F10 were 
considered best formulations. (Table: 6, Fig 2&2A) 
To analyze the pattern of drug release, the drug release data of 
the best formulations were subjected to release kinetics 
studies. The results show that formulations depict zero order 
release pattern where the prime mechanism is diffusion 
controlled (Table. 7).  
For phase II experiment, new combination of antihypertensive 
drugs, Nebivolol hydrochloride and valsartan were chosen 
based on the similarities with the model drugs Amlodipine 
besylate and Metoprolol succinate. In the chosen best 
formulation F1, F2, F3, F4, F5 and F10 keeping all excipients 
and their composition same, the model drugs were replaced 
with the test drugs under consideration. Bilayer tablets were 
formulated in the similar way and all precompression and post 
compression parameters analyzed in the same manner. The 
results are shown in (Table: 9, 10, and 12). The results are all 
within limits and nearly similar to the model drugs. The drug 
release profile of Nebivolol Hydrochloride is shown in (Table 
no: 14, fig 4 &4A) and release profile of Valsartan is shown in 
(Table no: 13, fig 3&3A). 
Table 15 shows the comparative release profile of Amlodipine 
besylate and Nebivolol hydrochloride from immediate release 
(IR) layers. The r value 0.98943 indicates a good correlation 
between the release profile of Amlodipine besylate and 
Nebivolol hydrochloride from the IR layer. The bar graph 
(Figure 5) of the release of these two drugs in 30 minutes 
indicate that Amlodipine besylate has greater percentage 
release (96-107%) at 30 minutes than Nebivolol 
hydrochloride. This may be due to its high solubility profile. In 
case of Nebivolol extent of release (79 – 92%) indicates an 
improvised solubility since it is a BCS class II drugs. This may 
be due the superdisintegrants sodium starch glycolate and 
cross carmellose sodium, which enhances the solubility.   
Table 16 shows comparative release profile of Metoprolol 
succinate and Valsartan from sustained release layer (SR). The 
r value in the range of 0.9998 indicates a good correlation 
between the release profile of Metoprolol succinate and 
Valsartan. Figure 6 shows the pattern of release of Valsartan 
which is almost similar to that of Metoprolol succinate in all 
formulations. The percentage drug release of Valsartan is less 
at the consecutive time points when compared to Metoprolol 
succinate. This might be due to its low solubility profile. 
CONCLUSION 
The present research was planned to develop an ideal dosage 
form that shall provide an optimal therapy for hypertension 
satisfying the patient requirement at the same time be 
formulation friendly. The ideology was to first standardize the 
process variables with well-accepted drugs so that the 
incorporation of a new combination drug would provide 
predictable results with a minimal trial runs. The results 
predict that if two drugs are similar in their physicochemical 
and pharmacokinetic parameters, their behavior will be 
comparable provided formulation variables remains constant. 
This study is a preliminary approach to develop a drug 
delivery system that could pave way to successful 
development of novel drug delivery system with the available 
generic drugs as model drugs. This approach can minimize the 
time and effort taken in developing a drug delivery system for 
new drug combinations. This work needs further extensive 
studies to justify this ideology.  
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